2. Current Impact of FDI
gh
KEY FDI IMPACTS ON THE IRISH
ECONOMY
- €110 BN Exports
- 240,000 Jobs in Total
- 55% of Corporation Tax
- €19 BN Expenditure
- €7 BN Payroll
- 73% of Business RD&I expenditure
WORLD LEADERS CHOOSE IRELAND
- 8 of the top 10 in ICT
- 8 of the top 10 in Pharmaceuticals
- 15 of the top 25 in Medical Devices
- More than 50% of the world’s leading
Financial Services firms
3. • Global Services
• High-end Manufacturing
• Research, Development & Innovation
Business Model Focus
Sectors
• Life Sciences - Pharma/Biopharma &
- Medical Devices
• Information & Communications Technology
• Financial Services
• Content Industry, Consumer & Business
Services
• Diversified Industries and Engineering
• CleanTech
IDA Focus
6. Ireland – major Life Sciences Hub
Biopharma Med Tech
Healthcare
Services
• 8 0f the top 10 Pharma
• 8 of top 10 and 15 of top 25
Medical Technologies
• 44,000 jobs
• Exports €51 Bn p.a.
• Numerous sub-suppiier and
service providers
7. Recent Lifesciences FDI
Investments
Investing €220m in a new fill finish vaccines facility (170 jobs)
Carlow. EMEA Service Centre in Dublin (150 Jobs).
EMEA Shared Services for 100 people, Cork.
Biologics, €400m investment.
Investing over €160m in R&D in Galway, Cork and Clonmel
Global manufacturing and development, 204 people, Dundalk
100 person manufacturing expansion in Co. Galway
250 person manufacturing expansion in Ballina
€30m investment in bio-analytical / chemistry services, 250 Jobs in Athlone
Expansion of €130m and 170 new jobs
European Shared Services Centre in Cork - 30 jobs
European Services Centre in Dublin, creating more than 200 job.
€50 million new manufacturing investment, creating 250 jobs in Clare
8. Global Lifesciences Industry
Drivers/Challenges
Pharma
• Patent cliff – increased
generics
• Pipeline Challenge
• Restructuring to
accommodate new reality
– M&A, cost reduction
• Increasing Regulatory
hurdles and costs
• US Healthcare reform –
biosimilars pathway
• Biologics
• Rise of Asia
• Ageing population
• Healthcare reform tax
• 510K regulatory pathway
changes USA
• Convergence – clear
coupling of devices and
tech.
• Asian market growing
strongly
10. Evolution of Pharma Bio
• Single Platform Technology
• API manufacturing
• Q&A labs
• Sophisticated
manufacturing
• Liquids
• Tabletting
• Creams
• Patches
• Molecular
diagnostics
• Reference
Global Sites
• Biopharma
• Shared
services -
Supply chain,
Regulatory,
Finance
• Commodity
medicines
• Self-Dx, Self
Treat
• Nutraceuticals
• Convergent
technologies
• Connected
Health
• Personalised
Medicine
• Combination
medical
products
• Medical Services
1980s 1990s 2000s 2020
11. 11
Horizon 2020 - Ongoing Evolution of Pharma Bio
2010-2015- Capturing and Delivering marketplace opportunites
• Integrating disease with lifestyle management
• Leveraging expertise in nutraceuticals, point of care assays
• Advancing molecular diagnostics and targetted therapies
• Utilising genetic testing & biomarkers in advanced clinical trials
• Developing convergent medical products
• Rise of bioinfomatics, population health strategies
Now - Building and Developing the sector
• Winning new biopharma investments
• Leveraging NiBRT to advance Biopharma Industry
• Enhancing Ireland’s small molecule Value Proposition
• Support vaccine development, generic reformulation, improved drug delivery
• Expanding mandates of top 30 companies “start earlier-finish later”
• Supporting new starts in packaging, tabletting, labelling, supply chain
• Expanding footprints into shared services, commercialisation, clinical trials
12. 12
Horizon 2020 - Ongoing Evolution of Pharma Bio
2020 Foresight
• Convergent medical management – drug & dynamic device
• Regenerative Health platforms in ageing, organ, joint replacement
• Connected Health platforms integrating e-health
• Cancer vaccines, targeted personal therapies
• Advancing silver care, aged care, focus on mental wellness
• Tailored health insurance per decade of life
• Development of “polypill”
• Integrated digital medical record and decision support
• Remote monitoring and treatment at home
• New bioactive materials and molecules from marine ecosystem
13. Ireland : A Proven Location for
Lifesciences Service Activities
14. Initiatives to protect and grow Industry
• Transformation –
– Technology uplift,
– Skills uplift
– Process development
– Product Development
– Energy Efficiency
– Operational excellence
• Strategic Sites and CMO
• NIBRT for Bio
• National Commercialisation centre for medical devices
• National competence centre for small molecule production
• International healthcare services centre
• Healthcare Innovation hub with HSE
• Research and Development Agenda
15. • TV Ads
• Live TV Interviews
• Online Media
• Print Media
• Airport Posters
• Press Interviews
• Web Optimisation
Integrated Communications Campaign